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Abstract
Background: Q fever is a neglected zoonosis caused by the bacterium Coxiella burnetii. The knowledge of the
epidemiology of Q fever in Kenya is limited with no attention to control and prevention programs. The purpose of
this review is to understand the situation of Q fever in human and animal populations in Kenya in the past
60 years, and help identify future research priorities for the country.
Methods: Databases were searched for national and international scientific studies or reports on Q fever. We
included studies and reports published between 1950 and 2015 if they reported on Q fever prevalence, incidence,
and infection control programs in Kenya. Data were extracted with respect to studies on prevalence of Coxiella
infections, study design, study region, the study populations involved, and sorted according to the year of the
study.
Results: We identified 15 studies and reports which qualified for data extraction. Human seroprevalence studies
revealed evidence of C. burnetii infections ranging from 3 to 35.8 % in all regions in which surveys were made and
two Q fever outbreak episodes. Coxiella burnetii infections found in cattle 7.4–51.1 %, sheep 6.7–20 %, camels 20–
46 %, and goats 20–46 % revealed variation based on ecoregions and the year of study. Farming and lack of
protective clothing were associated with increased seropositivity among humans. However, high quality data is
lacking on Q fever awareness, underlying cultural-economic factors influencing C. burnetii infection, and how the
pathogen cycles may be embedded in livestock production and management systems in the economically and
ecologically different Kenyan regions. We found no studies on national disease incidence estimates or disease
surveillance and control efforts.
Conclusion: Coxiella burnetii infections are common in human and in a wide range of animal populations but are
still unrecognized and underestimated thus presenting a significant human and animal health threat in Kenya. The
factors influencing pathogen transmission, persistence and spread are poorly understood. Integrated disease
surveillance and prevention/control programs are needed in Kenya.
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Background
Q fever is an acute (on occasion chronic) zoonotic
disease of great public health importance worldwide.
The disease is caused by an obligate gram-negative
bacterium; Coxiella burnetii [1]. Coxiella (C). burnetii
belongs to the genus Coxiella of the gamma subdivision
of Proteobaccteria along with the genera Legionella,
Francisella, and Rickettsiella. Unlike the other members
of Proteobaccteria, C. burnetii is highly resistant to ad-
verse physical conditions and chemical agents, so it can
survive for months and even years in the environment.
Its preferred target cells are macrophages located in
body tissues and the monocytes circulating in the blood
stream [2]. C. burnetii exists in two distinct antigenic
forms, the phase I and phase II bacterial variants which
can be discriminated by the surface lipopolysaccharide
(LPS) composition. This antigenic variation is important
for serological diagnosis and pathogenesis. Phase I vari-
ants are the highly infectious forms found in naturally
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infected hosts whereas phase II variants are less infec-
tious and are obtained after serial passages in cell culture
systems or embryonated eggs [3].
Domestic animals such as cattle, sheep and goats act
as the major reservoirs of C. burnetii which can infect a
large variety of animals, humans, birds, and arthropods
[4–7]. Human infection results from inhalation of
contaminated aerosols, consumption of contaminated
unpasteurized dairy products, direct contact with con-
taminated milk, urine, feces, or semen of infected ani-
mals, and tick bites [8, 9]. Clinical presentation is
nonspecific and highly variable ranging from asymptom-
atic infection (60 %) or self-limiting febrile illness associ-
ated with fatigue, headache, general malaise, myalgia,
arthralgia, to atypical pneumonia(rapidly progressive
courses may occur) and/or hepatitis. Less frequent com-
plications include endocarditis, osteomyelitis and aseptic
meningitis. About 1–2 % of acute symptomatic cases
may develop chronic disease [10, 11]. Q fever is consid-
ered to be an occupational disease of people who have
intimate contact with animals or their products such as
veterinarians, farmers, abattoir workers, and laboratory
workers [12]. There is emerging evidence of C. burnetii
as a cause of non-malaria febrile illness and community
acquired pneumonia in many developing countries
[13–18], but hospital based diagnosis of Q fever in
Kenya is uncommon. The lack of attention is mainly
due to scarcity of available data and the perceived
low clinical relevance of Q fever in relation to other
endemic fevers. As a result, the disease might often
be underreported and the disease burden grossly
under-estimated [19].
In animals, Q fever is frequently asymptomatic.
Sheep and goats may exhibit abortion, stillbirth, pre-
mature delivery, and delivery of weak offspring while
cattle and camel may develop infertility, metritis, and
mastitis [20, 21]. Animal studies have demonstrated
that vaginal mucus, feces, and urine are the common
shedding route and means for environmental contam-
ination through kidding and effluent mismanagement
[22, 23]. Mammals also considerably shed C. burnetii
in milk and thus consumption of contaminated
unpasteurized milk or dairy products can be a signifi-
cant source of human infection [24]. Similar to
humans, Q fever is under appreciated as cause of ani-
mal disease in Kenya possibly leading to persistence
of the infection in animal herds, impacting on live-
stock productivity, and acting as sources of infection
for humans [15].
The epidemiology of Q fever in Kenya is poorly
understood due the apparent neglect of the disease by
both medical and veterinary personnel and the limited
capacity to enable meaningful epidemiological surveys.
Therefore, we reviewed the literatures on Q fever among
human and animal populations in Kenya, from 1950 to
2015 to understand the epidemiological features of the
disease. The study also hoped to derive appropriate les-
sons from the Kenyan situation, and to identify the exist-
ing knowledge gaps on the C. burnetii infections in
humans and animals, and the disease control programs.
Methods
Search
Databases including CABDIRECT, Science Direct,
PubMed, and Google scholar were used for the searches.
Available unpublished reports and theses from Kenyan
university libraries and government departments were
systematically searched. Other related articles emerging
during the searches were also considered as sources of
additional information. The searched publications were
reviewed and relevant information was retrieved. The
following keywords were used to perform the searches:
‘Coxiella in Kenya’ ‘Q fever in Kenya’ ‘Q fever in humans
and animals in Kenya’, ‘Coxiella in humans and animals
in Kenya’ and ‘zoonotic diseases in Kenya’. Studies or ar-
ticles were included if they provided information on Q
fever/Coxiella burnetii prevalence, disease incidence or
outbreak, and infection control programmes in Kenya.
Bibliographies of selected papers were also reviewed and
grey literature searches performed for additional infor-
mation. The studies or reports with unrelated reports
were then excluded. The collected studies were reviewed
and classified based on the study group (animals,
humans and arthropods) and sorted according to the
year of the study. All studies in humans indicating either
acute or chronic disease were included. The seropositiv-
ity was used to describe serologic reactions that met the
recommended titer cut-offs of the respective test method
used. The clinical disease status was reported if the




In this review, 15 articles including published papers,
conference abstracts/posters, student theses and govern-
ment reports were ultimately identified and reviewed.
These included nine (9) studies on humans [26–34], four
(4) on animals [35–38], two (2) on ticks [17, 39], and
two (2) studies on both animals and humans [17, 29]
(Fig. 1). These studies differed in the methodological de-
signs such as sample size, method of sample selection
and collection, diagnostic criteria, and had limitations
associated with the small scale cross-sectional epidemio-
logical studies. For instance, five of these reports were
case studies; two were outbreak reports whilst three
studies were retrospective sero-epidemiological studies.
The latter utilized either banked sera collected or
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submitted to research laboratories or specialized hospi-
tals for disease diagnosis and did not provide proof of
random sampling, hence sampling bias may have been
significant in these studies.
Evolution of the number of publications
The first publication of Q fever dates back to 1950s. The
period from 1950 and 1976 was characterized by eight
regional studies. This was then followed by a 32 year
period (1971–2008) of no prevalence/incidence, except
for an outbreak report documented in 2000. A slow in-
crease of regional studies was found between 2008 and
2014 (Fig. 2).
Disease attributed to C. burnetii in humans (Q fever)
The first human case of Q fever was reported in 1952 in
a human clinical case in Nairobi [26]. Between 1955 and
1956, 17 more patients admitted to hospitals in Nairobi
and Nakuru towns were found to have Q fever. These
presented with febrile illness previously suspected and
treated for viral pneumonia, malaria or other tropical fe-
vers. Eventually, laboratory screening revealed that they
were seropositive for C. burnetii. All these patients with
exception of one were adult immigrants [27, 28]. A study
conducted from 1967 to 1968 using archived sera ob-
tained from hospitals in Western, Rift Valley, Central,
Eastern, and Coast provinces of Kenya demonstrated an
average seroprevalence of 35.8 % [29]. In the study, C.
burnetii antibodies were detected in samples from all the
participating hospitals. Two Q fever outbreaks were de-
scribed in 2000 and 2014 involving 50 safari travelers
[30] and 31 individuals in a small village in Rift Valley
Province [31], respectively. Six deaths were reported in
the latter outbreak. One of five Q fever cases diagnosed
in 2008 among western travelers/tourists returning from
tropics with fever was from Kenya [32]. A seropreva-
lence survey on banked sera of febrile patients treated in
a rural clinic in western Kenya recorded seropositivity of
30.9, with 3 % of patients who had been diagnosed with
acute lower respiratory infections (ALRI) being found to
have acute Q fever [17]. A study by Cook et al. [33] re-
ported C. burnetii seroprevalence of 4.5 % in abattoir
workers in western Kenya while Mwololo et al. [34]
found 26.8 % seropositivity in individuals in Bura district
where mixed crop farming and pastoralism are prac-
ticed. The findings in these studies were recently pre-
sented at international conferences [33, 34].
Coxiella burnetii infection in animals (Coxiellosis)
Serological surveys conducted in 1956 revealed 33.8, 7.4
and 75 % (3 of 4 dogs) seroprevalence in sheep, cattle
and dogs, respectively from Central province, while
Fig. 1 Search strategy and paper selection flowchart
Fig. 2 Number of publications and study groups included in the review, per 20 years period
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North Rift region showed seroprevalence of 20 and
51.1 % in camels and cattle respectively [35, 38].
Brotherston and Cook (1956) found a higher C. bur-
netii seroprevalence (51.1 %) in cattle from the same
region in the same year [28]. The study of Heisch et
al. [36] found 2.6 % of cattle and 6.7 % sheep to be
seropositive for C. burnetii in parts of Eastern prov-
ince [36]. The study also showed a prevalence of
about 13 % in 12 different species of wild rodents.
The bacteria were detected in 81 organ pools (brain
or spleen) of seropositive Lemniscomys spp. A 1976
study using banked sera from domestic animals (cat-
tle, sheep and goats) from five administrative prov-
inces (Western, Rift Valley, Central, Eastern, and
Coast) showed that the prevalence in each of the re-
gions ranged from 10–42.5 % [29]. Recently, Knobel
et al. [17] reported high Coxiella seropositivity in cat-
tle (28.3 %), goats (30 %), and sheep (18.2 %) in the
western region [17]. A more recent study in mixed
domestic animal-wildlife ranches of lower rift region
found variation in seroprevalence among domestic an-
imals; camels (46 %), goats (40 %) and sheep (20 %),
respectively [37].
Coxiella in ticks
Two studies described the presence of Coxiella in ticks.
In 1962, Heisch et al. isolated C. burnetii by inoculating
guinea-pigs with samples of ticks obtained from rodents
in Nairobi, Rift Valley, and Eastern Provinces [39]. The
study by Knobel et al. [17] detected Coxiella DNA in
50 % of tick pools obtained from domestic animals in
Western Kenya. The highest prevalence was found in
Haemaphysalis leachi [17].
Risk factors
The study by Mwololo et al. (2014) on possible risk
factors for Q fever infections in humans, identified
increased age and farming as risk factors for seroposi-
tivity [34], while Cook et al. (2014) identified alcohol
intoxication status of abattoir workers at work and
lack of appropriate protective clothing as risk factors
for Coxiella infection [33].
Q fever diagnosis
Previous studies and reports in Kenya mainly utilized
Complement Fixation Test (CFT) [26–29, 35–39] and
only recently Enzyme-Linked Immunosorbent Assay
(ELISA) [17, 31, 33, 34] and Immuno Fluorescence
Assay (IFAT) [17] diagnostic assays were used to detect
the presence of Coxiella antibodies in humans and ani-
mals. The study by Heisch et al. [39] demonstrated sero-
conversion of guinea pigs inoculated with ticks and
organ pool samples obtained from wild rodents towards
a range of rickettsial pathogens including Coxiella [39].
We found no study in which cell culture or PCR assays
(that are widely considered as the gold standard for diag-
nosis for Q fever) were used.
Q fever control programmes: One health approach
The government of Kenya in realization of the need
for concerted inter sectoral (one health) approach in con-
trol of zoonotic diseases, formed the Kenya Zoonotic
Diseases Unit (ZDU) in 2011. This intergovernmental unit
aimed to establish collaborative programmes for effective
prevention of zoonotic diseases in Kenya. However, we
found no study or reports describing Q fever vaccination
or disease awareness/control programmes in Kenya during
our searches. At the time of this review, the disease was
neither a notifiable disease nor listed in the priority
zoonotic diseases list for Kenya [31].
Discussion
The past surveys show strong evidence of Q fever ex-
posure in animals and humans in all regions in which
studies were conducted and the seroprevalence rates
appear high. This is in contrast to the scarce litera-
ture available (Table 1). Though the first Q fever case
was reported 63 years ago in Kenya [26, 35], only
limited high quality epidemiologic studies utilizing
randomly sampled human-animal populations for
Coxiella have been conducted. Available studies were
mainly retrospective using archived samples either
submitted to reference laboratories or collected in
hospitals for other diseases diagnosis resulting in sam-
pling bias. We found no descriptions of official na-
tional disease surveillance and reporting or control
programs in the published literatures. This knowledge
gap highlights the need for more representative epi-
demiological studies in the country to elucidate the
exact disease burden and pathogen transmission dy-
namics involved. The high seroprevalence of human
antibodies against Coxiella antigens in the previous
studies (3–35.8 %) suggests that cases are often mis-
diagnosed and/or unrecognized potentially leading to
wrong patient management. This is a great challenge
also in many sub-Saharan Africa countries where
other tropical fevers such as malaria, typhoid, rota-
virus and pneumonia are endemic. These infections
present with similar symptoms making their diagnosis
difficult leading to systematic under-reporting in the
human health system [40, 41]. Studies in neighboring
countries have reported comparable Coxiella seropositiv-
ity in humans, i.e., in Tanzania (3.9–20.3 %) [13, 19, 42], in
Ethiopia (6.5 %) [43], and in Sudan (10 %) [44].
Q fever is widely classified as an occupational disease
for those who have close contact with animals or their
products. Lack of appropriate personal protective
clothing, present or past residing in a farm are reported
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to increase ones odds for Coxiella seropositivity [9, 12].
Farming, alcohol intoxication status of abattoir workers
and lack of appropriate protective clothing during work
were associated with seropositivity in Kenya [33, 34].
However, high quality data related to Q fever awareness
or underlying social-economic or cultural factors predis-
posing humans to C burnetii infection are lacking. No
studies were found on populations considered at high
risk of infection such as veterinarians, retail butchers,
pastoralist communities, and mixed livestock-crop pro-
duction farmers. A study in Egypt on high risk groups
reported high seropositivity (16 and 22 %) in populations
living in close contact with animals and those living in
rural establishment [45]. In contrast, a study in Chad
Table 1 Reviewed studies and reports of C. burnetii infection in humans and animals in Kenya
Study year Region Species Prevalence/reactors Inclusion criteria Reference
1952 Central Human 1 case Case study Harris, B.P
1955 Rift valley Human 13 cases Case study Craddock, A.L. and J. Gear
1956 Central Human 4 cases Case study Brotherston, J.C. and E.R. Cooke
Rift valley Cattle 20 of 35 cases
1956 Central Cattle 7.4 % Retrospective epidemiological study Brown, R.D
Central Goats 33.8 % Vogel L.C et al.
Rift valley Camel 20 %
Central Dogs (3 of 4) cases Case study
1960 Multiple regions Rodent 13 % Seroepidemiological study Heisch, R.B.
1962 Eastern Cattle 2.6 % Seroepidemiological study Heisch, R.B., et al.
Eastern Sheep 6.7 %
Multiple regions Ticks 2.3 %
1976 Western Human 45.7 % Retrospective epidemiological study Vanek, E. and B. Thimm
Cattle 32.9 %
Goats 30
Rift valley Human 20.3 %
Cattle 22.9 %
Central Human 12 %
Cattle 10 %
Eastern Human 41 %
Cattle 31.9 %
Coast Human 50.4 %
Cattle 42.5 %
2000 Rift valley Human 8 % Outbreak investigation Potasman, I., et al.
2008 Unknown Human 1 case Case study Ta, T., et al.
2013 Western Human 3 % Epidemiological study Knobel, D.L., et al.





2014 Rift valley Camel 46 % Epidemiological study DePuy, W., et al.
Goats 40 %
Cattle 20 %
2014 Coast Human 26.8 % Seroepidemiological study Mwololo D. K et al.
2014 Western Human 4.5 % Seroepidemiological study Cook, E.A. et al.
2014 Rift valley Human 54.8 % Outbreak investigation ZDU, Kenya
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found low seropositivity (1 %) in similar high risk groups
[46]. A study in Tanzania demonstrated an association
between Q fever onset and dry season [18]. Our review
did not identify investigations on how the pathogen cy-
cles are potentially embedded in livestock production
and management systems in the economically and eco-
logically heterogeneous regions of Kenya.
We identified no study in human populations from
northern eastern and upper eastern regions of Kenya
but the available animal reports from similar popula-
tions in north rift regions revealed high exposure
rates of 51.1 % and 20 % in cattle and camel, respect-
ively (Fig. 3) [29, 35]. Epidemiological studies are
needed in these high risk regions of Kenya because
the communities in these regions practice mixed live-
stock ranching-and-wildlife conservancy systems and
predominantly individual livestock-based pastoralism
with high rates of livestock-wildlife interaction. Seropreva-
lence of C. burnetii of 7.4–51.1 % in cattle, 20–46 % in
goats, 6.7–20 % in sheep, 20 and 46 % in camel and 13 %
in rodents have been reported [18, 29, 35, 37, 38]. We
found no distinct variation in C. burnetii infections among
the animal species and the different administrative prov-
inces. However, there were seemingly higher infections
(28.2–57.1 %) reported in livestock from arid and semi-
arid ecoregions of Rift Valley, Coast, Western and Eastern
provinces when compared to Central and Nairobi.
Though the precise reason for this variation is not clear, it
is possible that specific local variation in prevalence exist
based on the differences in animal husbandry practices,
human and livestock density patterns and the differences
in livestock infection in each of the ecoregions. Therefore,
if no appropriate control strategies are implemented, the
infected animals may continue to serve as reservoirs and
source of infection to the uninfected animals and humans.
Moreover, data on other common domestic animals in
Kenya such as pigs, donkeys, and cats are not available.
Therefore, the role of these domestic animals or ruminant
wildlife animals as reservoirs and transmission of Coxiella
need to be investigated. Surveys in the neighboring coun-
tries have reported Coxiella seropositivity with similar
ranges in domestic animals, i.e., in Tanzania (13.3 % cattle,
13.6 % goats, 17.1 % sheep) [42], Ethiopia (31.6 % cattle,
54.2 % goats, 90 % camel) [47] and Sudan (24 % goats,
40.4 % cattle, 53 % goats, 62.5 % sheep [48, 49]. This epi-
demiologic status may be linked to the unregulated cross-
border livestock movements through trade routes and no-
madic movements between these countries in search of
pasture and watering points that may allow the entry and
spread of infected herds. These findings call for further re-
search to elucidate the epidemiology of Q fever in linked
animal and human populations in large representative
surveys (within this african region) to enable assess
the correlations of the disease incidence with agricul-
tural production systems, geographical and climatic
conditions and the animal husbandly practices.
Cell culture of Coxiella in a variety of culture media is
considered as the gold standard for diagnosis for Q
fever. However, the process is usually time consuming
and difficult. Moreover, Coxiella is a highly hazardous
pathogen whose isolation requires biosafety level 3
(BSL3) laboratory facilities because of its high infectivity
potential [9]. As a result, this requires huge investments
in terms of specialized skills and equipment. These are
not affordable in many developing countries such as
Kenya and thus previous epidemiological studies based
on bacterial isolation have not been feasible. Recently, a
cell-free laboratory culture medium whose composition
mimics that of the host cells phagolysosome has been
developed and it is undergoing evaluation and validation
[2]. This discovery may therefore permit culture based
epidemiological studies in resource limited settings such
as Kenya in future. Detection of C. burnetii DNA in
various samples by a range of Polymerase Chain Reac-
tion (PCR) assays is progressively becoming available
and is considered useful especially in the acute clinical
stages of the illness when seroconversion is not sufficient
to be detected by serological methods [50]. Similarly, the
cost of the respective equipment and technical expertise
makes it difficult for adoption for routine hospital based
testing or to enable seroepidemiological research in
many developing countries. Despite the availability of
these diagnostic facilities in specialized and research
laboratories in Kenya, Q fever diagnosis is still not
considered during routine human and animals’ disease
Fig. 3 Map of Kenya showing eight administrative provinces
(numbered) and spatial distribution of the previous studies. Key: Blue
triangle: human studies; yellow triangle: linked human and animal
studies; red dots: animal studies; 1: Central; 2: Coast; 3: Eastern; 4:
Nairobi; 5: North eastern; 6: Nyanza; 7: Rift valley; 8: Western
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diagnosis systems. This can be attributed to the fact
that these facilities are located in major towns which
are not readily accessible to the regional health care
facilities. Efforts to establish a regional laboratory in
at least each county with facilities for performing reli-
able serological assay such as ELISA or serum based
real-time qPCR are highly recommended. This ap-
proach will shorten the time needed to gain a sensi-
tive diagnosis in patients presenting with fever of
unknown origin and enable appropriate management
of the patients.
As shown for other countries, controlling of the dis-
ease in animals contributes significantly to the decreased
incidence in humans [51]. Vaccination of animals against
Q fever could therefore present an effective control
method. Until now, several vaccines have been devel-
oped consisting of inactivated whole phase 1 bacteria.
However, many were shown to be nonprotective and
presented several limitations such as short term protec-
tion and the inability to distinguish between vaccinated
and naturally infected animals. Currently, prevention of
Q fever in some European countries includes animal
vaccination with the non-fully licensed inactivated phase
I vaccine, Coxevac (CEVA-Santé Animale, France), after
a focus of Q fever has been determined [9]. Several dif-
ferent vaccines have been developed for use in humans.
These are mainly composed of a live attenuated strain or
subunit vaccines [2, 52]. Despite demonstrating antige-
nicity and immunogenicity in many trials, humans
develop severe reactions to the vaccinations making
many of these vaccines effective to only individuals that
have no previous exposures. This necessitates extensive
screening before administration to having a direct im-
pact on the final cost of the vaccine [53]. Presently,
the considered effective vaccine is a formalin killed
whole-cell vaccine (Qvax, CSL Limited, Australia) that
is licensed for use in Australia, especially in high risk
occupational groups. The availability of the vaccines
present a great challenge in most of the developing
countries and is currently not performed in Kenya.
Limitations of the data
Lack of national level surveys and individual studies not
being representative might lead to inappropriate esti-
mates of Q fever prevalence. Also, the authors of the
included studies have not taken into account the con-
founding bias and this may affect the true estimate.
Conclusions
This is the first review of Q fever disease in animals and
humans in Kenya. The findings from past literatures
strongly suggest that C. burnetii infections are common
in both humans and animals. Social-economic factors
and lack of disease surveillance/control programmes
present a significant risk of pathogen persistence and
transmission in human and animal populations. More
research is needed to elucidate the epidemiology of Q
fever in linked animal and human populations in order
to understand in greater details the human and animal
exposure in different ecoregions and the correlations
with disease incidence in different agricultural produc-
tion systems. As with all zoonotic diseases, close collab-
oration between veterinary and medical authorities (One
Health) both on national and regional levels is necessary
in order to establish an integrated health surveillance
and prevention/control programs for the disease in
Kenya.
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